Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | APEX1 | P27695 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | DAO | P14920 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3605212 | 0.84 | L3MBTL1 (0.45) | L3MBTL1TDP1TP53KMT2AALDH1A1 | |
| SCHEMBL21049227 | 0.82 | L3MBTL1 (0.41) | L3MBTL1TDP1TP53KMT2AALDH1A1 | |
| SCHEMBL28257547 | 0.82 | L3MBTL1 (0.45) | L3MBTL1TDP1TP53KMT2AALDH1A1 | |
| SCHEMBL38507 | 0.82 | L3MBTL1 (0.45) | L3MBTL1TDP1TP53KMT2AALDH1A1 | |
| SCHEMBL31253429 | 0.81 | L3MBTL1 (0.37) | L3MBTL1TDP1TP53KMT2AALDH1A1 | |
| SCHEMBL28829681 | 0.80 | L3MBTL1 (0.44) | L3MBTL1TDP1TP53KMT2AALDH1A1 | |
| Hydrochloric Acid SCHEMBL4441902 | 0.80 | L3MBTL1 (0.44) | L3MBTL1TDP1TP53KMT2AALDH1A1 | |
| Bromide SCHEMBL28497865 | 0.80 | L3MBTL1 (0.44) | L3MBTL1TDP1TP53KMT2AALDH1A1 | |
| Bicarbonate SCHEMBL28887905 | 0.80 | L3MBTL1 (0.44) | L3MBTL1TDP1TP53KMT2AALDH1A1 | |
| Calcium SCHEMBL31344979 | 0.80 | L3MBTL1 (0.44) | L3MBTL1TDP1TP53KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8653048-B2 | Prodrugs based on gemcitabine structure and synthetic methods and applications thereof | SANLUGEN PHARMATECH LTD. (CN) | 2014-02-18 | — | — | US | claimed |
| US-20120088908-A1 | Prodrugs Based on Gemcitabine Structure and Synthetic Methods and Applications Thereof | SANLUGEN PHARMATECH LTD. (CN) | 2012-04-12 | — | — | US | claimed |
| EP-2423215-A1 | PRODRUGS BASED ON GEMCITABINE STRUCTURE AS WELL AS SYNTHETIC METHOD AND APPLICATION THEREOF | Sanlugen Pharmatech Ltd. (CN) | 2012-02-29 | — | — | EP | claimed |
| CN-116715836-A | Polyester with antibacterial and antiviral functions and preparation method and application thereof | 东华大学 | 2023-09-08 | — | — | CN | disclosed |
| US-8653048-B2 | Prodrugs based on gemcitabine structure and synthetic methods and applications thereof | SANLUGEN PHARMATECH LTD. (CN) | 2014-02-18 | — | — | US | disclosed |
| US-20120088908-A1 | Prodrugs Based on Gemcitabine Structure and Synthetic Methods and Applications Thereof | SANLUGEN PHARMATECH LTD. (CN) | 2012-04-12 | — | — | US | disclosed |
| EP-2423215-A1 | PRODRUGS BASED ON GEMCITABINE STRUCTURE AS WELL AS SYNTHETIC METHOD AND APPLICATION THEREOF | Sanlugen Pharmatech Ltd. (CN) | 2012-02-29 | — | — | EP | disclosed |
| US-5770340-A | USING ELECTROGRAPHIC PRINTING PLATE HAVING ELECTROCONDUCTIVE SUPPORT WITH PHOTOCONDUCTIVE LAYER CONTAINING INORGANIC PHOTOCONDUCTOR, SPECIFIC SENSITIZING DYE AND BINDER, ALSO WITH BACKING HAVING LOW ELECTRICAL RESISTANCE | FUJI PHOTO FILM CO., LTD. (JP) | 1998-06-23 | — | — | US | disclosed |
| US-5677098-A | USING CYANINE DYE | FUJI PHOTO FILM CO., LTD. (JP) | 1997-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088908-A1 | Prodrugs Based on Gemcitabine Structure and Synthetic Methods and Applications Thereof | TYMP, DCTD, GLS2 | L3MBTL1 497/4885TDP1 1766/4885TP53 254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.